Protein Kinase Inhibitors

"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that inhibit PROTEIN KINASES.

Descriptor ID	D047428
MeSH Number(s)	D27.505.519.389.755
Concept/Terms	Protein Kinase Inhibitors Protein Kinase Inhibitors Inhibitors, Protein Kinase Kinase Inhibitors, Protein

Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protein Kinase Inhibitors [D27.505.519.389.755]

Below are MeSH descriptors whose meaning is related to "Protein Kinase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".

Protein Kinase Inhibitors
Janus Kinase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 145 publications over 25 distinct years, with a maximum of 16 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1997	0	1	1
2002	1	0	1
2004	0	2	2
2005	2	3	5
2006	0	1	1
2007	1	0	1
2008	5	4	9
2009	1	4	5
2010	2	5	7
2011	3	1	4
2012	3	5	8
2013	4	8	12
2014	1	7	8
2015	4	4	8
2016	5	7	12
2017	4	5	9
2018	5	1	6
2019	6	10	16
2020	3	5	8
2021	3	0	3
2022	0	8	8
2023	0	2	2
2024	3	4	7
2025	1	0	1

Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.

Banas V, Elfawal MA, Rosa BA, Mahoney M, Kauffman J, Goetz E, Chen P, Aroian RV, Mitreva M, Janetka JW. Discovery of Human PIM Kinase Inhibitors as a Class of Anthelmintic Drugs to Treat Intestinal Nematode Infections. ACS Infect Dis. 2025 Feb 14; 11(2):506-517.

View in: PubMed
Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.

View in: PubMed
Collins SP, Shotwell MS, Strich JR, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock K, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine NM, Tiffany B, Douglas I, Levitt J, Ginde AA, Hager DN, Shapiro N, Duggal A, Khan A, Lanspa M, Chen P, Gentile N, Harris E, Gong M, Sellers S, Goodwin AJ, Tidswell MA, Filbin M, Desai N, Guti?rrez F, Estrada V, Burgos J, Boyles T, Pa?o-Pardo JR, Hussen N, Rosenberg Y, Troendle J, Bernard GR, Bistran-Hall AJ, Walsh K, Casey JD, DeClercq J, Joly MM, Pulley J, Rice TW, Schildcrout JS, Wang L, Semler MW, Self WH. Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. JAMA Netw Open. 2024 Dec 02; 7(12):e2448215.

View in: PubMed
Nagesh PT, Cho Y, Zhuang Y, Babuta M, Ortega-Ribera M, Joshi R, Brezani V, Patel A, Datta AA, Brezani V, Hsieh YC, Ramos A, Mehta J, Copeland C, Kanata E, Jiang ZG, Vlachos I, Asara J, Szabo G. In vivo Bruton's tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesis. Sci Transl Med. 2024 Aug 07; 16(759):eadg1915.

View in: PubMed
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.

View in: PubMed
Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. Eur J Cancer. 2024 May; 202:114009.

View in: PubMed
Kim EJ, Reusch DB, Anthony H, Schmidt B, Corey K, Degar B, Huang JT. Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib. Br J Dermatol. 2024 01 23; 190(2):283-284.

View in: PubMed
Kennedy A, Patel S, Ramanathan M, Gerber J, Cerny J. Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center. Ann Hematol. 2024 Mar; 103(3):1031-1033.

View in: PubMed
Malvi P, Chava S, Cai G, Hu K, Zhu LJ, Edwards YJK, Green MR, Gupta R, Wajapeyee N. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. Cell Rep Med. 2023 11 21; 4(11):101285.

View in: PubMed
Kim DY, Swetter SM, Huhmann L, Dizon MP, Ferguson JM, Osborne TF, Spence AC, Ziad A, Fillmore N, Hartman RI. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma. J Am Acad Dermatol. 2024 03; 90(3):620-623.

View in: PubMed

People

Explore

Similar Concepts

Top Journals